Wire · opportunities
Viking Therapeutics' Oral Obesity Drug Advances to Phase 3 Testing. Is Now the Time to ...
◆ Sectors
◆ Geography
◆ Source
◆ Verified
Fusion42 · 10 October 2026 · Fusion42 review
Viking Therapeutics is advancing its oral obesity drug candidate VK2735 to phase 3 trials following promising phase 2 weight loss results, despite concerns about side effects and treatment discontinuation. The drug competes in a fast-moving market dominated by injectable therapies from companies like Eli Lilly, requiring Viking to demonstrate strong efficacy and tolerability to succeed.
This Wire brief sits within Fusion42's coverage of Biotech.
◆ ◆ The Wire takeaway
Weight loss drug founders facing dominance by injectables can now see oral therapies nearing critical vetting. You must prepare for tougher clinical hurdles and prescriber scepticism over side effects.
◆ Coverage
1 source · 10 Oct 2026
◆ Related on Wire
◆ Topics